ERBB2 and neoplasm: Our study shows that HER2-DC1 i.t. combined with anti-HER2 antibodies treatment is more effective than standard chemotherapy paclitaxel combined with anti-HER2 antibodies and induces complete tumor regression in the HER2pos BC model.